Customized Preclinical Solutions for Eosinophilic Esophagitis (EoE) Model Development and Drug Research
Download
Eosinophilic esophagitis (EoE) is a chronic, allergen-mediated inflammatory condition of the esophagus, characterized by dense eosinophilic infiltration, esophageal dysfunction, and tissue remodeling.
As a leading preclinical research service provider, Protheragen delivers comprehensive, end-to-end solutions for EoE research. Designed to meet the specific needs of drug and diagnostic developers, provides fully customizable EoE model development alongside integrated preclinical research services, from disease modeling through therapeutic efficacy evaluation. Enables accelerated translational research by combining disease-relevant animal models with specialized assay platforms in one seamless workflow.
Overview of Eosinophilic Esophagitis (EoE) Models
Establishing a robust EoE model requires the precise replication of the Th2-type immune response and the subsequent structural remodeling observed in human patients. Current modeling strategies utilize specific allergen sensitization, such as Ovalbumin (OVA) or Aspergillus fumigatus, alongside innovative cytokine-driven approaches (e.g., IL-13 overexpression) to induce hallmark features including intraepithelial eosinophilia, basal zone hyperplasia, and subepithelial fibrosis. These models serve as essential tools for dissecting the mechanisms of esophageal remodeling and assessing the efficacy of emerging biologic and small-molecule interventions.
Applications of Eosinophilic Esophagitis (EoE) Models
Utilizing advanced EoE models provides a critical platform that mirrors human Th2-driven esophageal inflammation, eosinophilic infiltration, and tissue remodeling, enabling rigorous investigation of disease pathogenesis, therapeutic intervention points, and diagnostic target validation. These models support a broad range of preclinical applications, including but not limited to:
Mechanism of Action (MoA) Studies
Systematically dissects the roles of signature type 2 cytokines (IL-4, IL-5, IL-13) and downstream chemokines such as eotaxin-3 in driving esophageal eosinophil recruitment, epithelial barrier disruption, and basal zone hyperplasia. Permits pathway-specific interrogation using neutralizing antibodies, knockout animals, or small molecule inhibitors.
Drug Efficacy Screening
Quantitatively assesses the ability of candidate compounds to reduce esophageal eosinophil counts to near-normal levels, resolve epithelial hyperplasia, and attenuate established subepithelial fibrosis. Supports dose‑ranging studies and head‑to‑head comparisons with standard‑of‑care agents such as topical corticosteroids or anti‑IL‑5 antibodies.
Biomarker Discovery and Validation
Identifies early and dynamic molecular signatures in serum, plasma, or esophageal tissue that correlate with disease activity, histologic severity, or treatment response. Enables validation of candidate biomarkers, including eosinophil peroxidase, major basic protein, eotaxin-3, and epithelial barrier proteins for potential diagnostic use.
Pathological Remodeling Analysis
Characterizes the progression from acute inflammation to chronic fibrostenotic disease. Evaluates changes in esophageal compliance, lamina propria collagen deposition, smooth muscle hypertrophy, and stricture formation. Provides a platform for testing anti-fibrotic agents combined with anti-inflammatory therapies in long‑term challenge protocols.
Workflow for Eosinophilic Esophagitis (EoE) Model Development
- Consultation and Model Selection: Defines study objectives (acute vs. chronic inflammation, fibrosis assessment, or therapeutic screening), preferred allergen (OVA, fungal extract, food protein), mouse strain (BALB/c, C57BL/6, or IL-13 transgenic), and required endpoints.
- Sensitization Phase: Involves systemic immunization via intraperitoneal or subcutaneous injection of allergen combined with an adjuvant to prime a Th2-dominant immune response.
- Challenge Phase: Delivers repeated intraesophageal or intranasal allergen challenges depending on chronicity needs.
- Monitoring and Sample Collection: Collects esophageal tissues at predetermined time points for histology (H&E, eosinophil peroxidase, Masson’s trichrome), snap-frozen samples for molecular analysis (qPCR for IL-4, IL-5, IL-13, eotaxin-3), and serum for allergen-specific IgE ELISA.
- Endpoint Assessment and Histopathology: Quantifies eosinophil infiltration, basal zone hyperplasia, dilated intercellular spaces, and subepithelial collagen deposition.
- Data Analysis and Reporting: Compares treated vs. control groups using statistical analysis. Provides a full study report including raw data, representative histology images, and interpretation of model performance relative to human disease.
Integrated Preclinical Research Services for Eosinophilic Esophagitis (EoE)
Provides a full suite of services that extend beyond model development, enabling seamless progression from disease induction to therapy evaluation. Covers the entire preclinical pipeline, from target validation and lead optimization through pharmacokinetics, toxicology, and regulatory‑directed safety studies. All studies are performed under rigorous quality standards.
Diagnostics Development Services
Develops and validates assays for EoE-specific biomarkers, including tissue eosinophil quantification, eotaxin-3 ELISA, and immunohistochemistry for epithelial barrier proteins (filaggrin, desmoglein-1).
Supporting the optimization of lead compounds, including biologics and topical formulations, through robust in vitro and in vivo efficacy testing.
Designs de novo EoE models based on allergen triggers, genetic backgrounds, or chronicity requirements, covering both in vivo and in vitro platforms.
Conducting rigorous PK/PD profiling and safety assessments to determine the metabolic fate and potential off-target effects of the candidate drug.
Case Study 01- IL-33 Induced EoE Model
A murine EoE model was established using recombinant mouse IL‑33 administered via intraperitoneal injection in C57BL/6 mice. The model group received multiple doses of IL‑33, while the control group received vehicle only following the same schedule. Key endpoints included body weight, esophageal weight, serum IgE levels, and flow cytometric analysis of eosinophil and neutrophil populations in blood and esophageal tissue.
Fig.1 Body weight changes during the study period. Data are presented as mean ± SEM (n=5).
IL‑33 challenge successfully induced hallmark features of EoE, including esophageal eosinophilia, tissue edema, and Th2‑associated immune responses. Esophagus weight and serum IgE levels were significantly elevated in the model group, indicating tissue edema and a systemic Th2‑driven immune response consistent with EoE pathology. The percentage of CD170+ eosinophils in blood was markedly increased after IL‑33 challenge, whereas Ly6G+ neutrophil counts in blood showed no significant change. In the esophagus, both CD170+ eosinophil infiltration and CD11b+ myeloid cell accumulation were substantially elevated in IL‑33‑induced animals.
Fig.2 Esophagus weight and serum IgE levels. Both parameters were significantly increased in IL‑33‑induced mice compared to controls. Data are presented as mean ± SEM (n=5; *p < 0.05).
Case Study 02- Oxazolone (OXA) induced model
An EoE model was developed in C57BL/6 mice by skin sensitization with oxazolone (OXA) followed by intraesophageal OXA challenge. The model group received both sensitization and challenge, whereas the control group received vehicle alone under the same schedule.
Fig.3 Serum IgE levels and histologic H&E score of the esophagus. Both were significantly elevated in OXA‑induced mice. Data are presented as mean ± SEM (n=5; **p < 0.01, *p < 0.05).
Serum IgE levels and histologic H&E scores of the esophagus were significantly elevated in OXA‑induced mice compared to controls, reflecting a systemic Th2‑biased response and local eosinophil infiltration. CD170+ eosinophils in both blood and esophageal tissue were markedly increased following OXA challenge, confirming successful induction of esophageal eosinophilia.
Fig.4 CD170+ eosinophils in blood and CD170+ eosinophils in the esophagus. Marked increases in CD170+ eosinophils were observed in both compartments after OXA challenge. Data are presented as mean ± SEM (n=5; *p < 0.05).
Why Choose Us?
- Deep Pathological Expertise: Leveraging a team of specialized pathologists and immunologists who possess an intimate understanding of the fibrostenotic progression in esophageal diseases.
- Customizable Research Platforms: Delivering bespoke model configurations that can be adjusted for acute inflammation or chronic remodeling, depending on the therapeutic window of the drug.
- High-Resolution Analytical Tools: Utilizing state-of-the-art quantitative histology, multiplex cytokine analysis, and transcriptomic profiling to provide a multidimensional view of drug impact.
- Accelerated Development Timelines: Streamlining the transition from model induction to final data delivery through an optimized project management framework and standardized SOPs.
Contact Us
Protheragen delivers robust, reproducible eosinophilic esophagitis (EoE) models paired with a complete range of preclinical research services, from model development and diagnostics to therapeutic efficacy and toxicology. Accelerates the translation of novel therapies and diagnostics for EoE by providing disease‑relevant platforms supported by deep immunological and histopathological expertise. For custom model design, study quotes, or technical consultation, please contact us .
Resource Download Request
Please complete the form to download the requested resources.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
- CAR-T Cell Therapy Development Service for Multiple Myeloma (MM)
- Rare Diseases Drug Discovery & Development
- Skin-on-a-Chip Model for Rare Skin Disease
- Your Trusted Partner in Rare Disease Drug Discovery and Development
- Customized Solutions for Hair-Bearing Skin Organoid Model Development
- Customized Solutions for Bronchiolitis Obliterans Syndrome Drug Discovery and Development
- Pulmonary Arterial Hypertension (PAH) Animal Model Service
- Customized Solutions for Food Allergy Animal Model
- Customized Solutions for Systemic Sclerosis (SSc) Animal Model Development
- Customized Solutions for Systemic Lupus Erythematosus (SLE) Model Development
- ImmuCell
- MitoClear
- Customized Solutions for Ankylosing Spondylitis Model Development and Preclinical Research
- Customized Preclinical Solutions for Eosinophilic Esophagitis (EoE) Model Development and Drug Research
- Preclinical Research Services for Primary Biliary Cholangitis (PBC) and Cholestatic Liver Disease Models